Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,180.74 +52.95 (+1.03%) Dow
38,852.27 +176.59 (+0.46%) Nasdaq
16,349.25 +192.92 (+1.19%) Bitcoin USD
63,385.55 -561.45 (-0.88%) CMC Crypto 200
1,367.24 +54.61 (+4.16%)
VRTX Jan 2026 260.000 call
| Previous close | 187.00 |
| Open | 187.30 |
| Bid | 176.00 |
| Ask | 185.00 |
| Strike | 260.00 |
| Expiry date | 2026-01-16 |
| Day's range | 187.00 - 187.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 11 |
GuruFocus.comVertex Pharmaceuticals Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Expansions
Comprehensive Analysis of Vertex Pharmaceuticals' Financial Performance and Strategic Initiatives
ReutersVertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments
(Reuters) -Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its blockbuster cystic fibrosis treatments. Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, digestive system and other organs - affects an estimated 105,000 people across 94 countries, according to data from U.S.-based CF Foundation. Vertex reported adjusted earnings per share of $4.76 on revenue of $2.69 billion, topping market estimates $4.06 on revenue of $2.58 billion, according to LSEG data, for the quarter ended March 31.
Business WireVertex Reports First Quarter 2024 Financial Results
BOSTON, May 06, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2024, and reiterated full year 2024 financial guidance.
